drugset / Trial / NCT06131918

Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy

NCT06131918

Phase 2 Completed 100 enrolled Khyber Medical University Peshawar
RandomizedParallel-groupSingle-blindTreatment

Summary

Type 2 DM subjects having numbness, tingling and paresthesia in hands and feet (neuropathy) will be recruited. Screening of neuropathy will be done by Michigan screening instrument. This will be followed by nerve conduction studies. Specific blood parameters will also be checked. The subjects will then be divided into four treatment arms. Three groups will receive single drug and the fourth one will receive all the three drugs. These will be given for four months. Follow up will be done every month. At the end of four months, they will be assessed for any improvement in neuropathy by using Michigan neuropathy instrument and nerve conduction studies. Blood parameters will also be measured again.

Timeline

Start
2023-01-09
Primary completion
2023-12-22
Completion
2024-05-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator ORGOTEIN Protein / enzyme biologic 250 mg
Comparator Resveratrol Small molecule 1500 mg
Comparator alpha-lipoic acid Small molecule 600 mg